William Blair Issues Optimistic Forecast for PTCT Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities researchers at William Blair raised their Q1 2025 earnings per share (EPS) estimates for PTC Therapeutics in a note issued to investors on Wednesday, May 7th. William Blair analyst S. Corwin now anticipates that the biopharmaceutical company will earn $10.04 per share for the quarter, up from their previous estimate of ($0.83). The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics' Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.36) EPS, Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at $6.47 EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($2.79) EPS.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, topping the consensus estimate of $0.85 by $9.19. The company had revenue of $1.18 billion during the quarter, compared to analysts' expectations of $437.16 million. The business's revenue for the quarter was down 9.6% compared to the same quarter last year. During the same period last year, the company earned ($1.20) earnings per share.

A number of other analysts also recently commented on the company. Royal Bank of Canada increased their price target on PTC Therapeutics from $57.00 to $58.00 and gave the company an "outperform" rating in a research report on Wednesday, May 7th. StockNews.com raised PTC Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, May 8th. Cantor Fitzgerald reduced their price objective on PTC Therapeutics from $113.00 to $112.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Bank of America raised PTC Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the company from $55.00 to $68.00 in a report on Friday, May 9th. Finally, Barclays cut their price target on PTC Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $61.92.

PTC Therapeutics Trading Up 0.9%

Shares of PTCT traded up $0.42 on Friday, reaching $46.81. 607,326 shares of the company's stock traded hands, compared to its average volume of 855,552. The stock has a market cap of $3.71 billion, a PE ratio of -7.88 and a beta of 0.52. The stock's 50 day simple moving average is $48.62 and its two-hundred day simple moving average is $47.09. PTC Therapeutics has a 52-week low of $28.72 and a 52-week high of $58.38.

Insider Activity at PTC Therapeutics

In related news, VP Mark Elliott Boulding sold 15,521 shares of PTC Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $53.30, for a total transaction of $827,269.30. Following the completion of the sale, the vice president now owns 103,901 shares of the company's stock, valued at approximately $5,537,923.30. This trade represents a 13.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Pierre Gravier sold 1,168 shares of PTC Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total value of $58,516.80. Following the sale, the chief financial officer now directly owns 75,603 shares of the company's stock, valued at $3,787,710.30. This represents a 1.52% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,305 shares of company stock valued at $1,682,755. Company insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On PTC Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in PTC Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 9,178,822 shares of the biopharmaceutical company's stock worth $414,332,000 after purchasing an additional 53,688 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of PTC Therapeutics by 13.2% in the 1st quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company's stock valued at $276,161,000 after acquiring an additional 632,049 shares during the last quarter. Toronto Dominion Bank bought a new stake in shares of PTC Therapeutics in the 4th quarter valued at about $148,363,000. Janus Henderson Group PLC lifted its stake in shares of PTC Therapeutics by 24.4% in the 4th quarter. Janus Henderson Group PLC now owns 2,325,915 shares of the biopharmaceutical company's stock valued at $105,015,000 after acquiring an additional 455,698 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in shares of PTC Therapeutics by 150.6% in the 4th quarter. Point72 Asset Management L.P. now owns 1,443,362 shares of the biopharmaceutical company's stock valued at $65,153,000 after acquiring an additional 867,502 shares during the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.